ASX:CUVClinuvel Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Clinuvel Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$23.00 +0.10 (+0.44 %) (As of 05/13/2020) Add Compare Share Today's RangeA$22.13Now: A$23.00▼A$23.0450-Day RangeA$19.87MA: A$21.97▼A$23.3552-Week RangeA$12.92Now: A$23.00▼A$45.88Volume124,193 shsAverage VolumeN/AMarket Capitalization$1.14 billionP/E Ratio75.91Dividend Yield0.10%BetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe skin disorders in Europe and Switzerland. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria that has completed Phase II and III trials in the United States and Europe. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited is headquartered in Melbourne, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Clinuvel Pharmaceuticals. Previous Next 2.4 Community Rank Outperform VotesClinuvel Pharmaceuticals has received 37 “outperform” votes. (Add your “outperform” vote.)Underperform VotesClinuvel Pharmaceuticals has received 41 “underperform” votes. (Add your “underperform” vote.)Community SentimentClinuvel Pharmaceuticals has received 52.56% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Clinuvel Pharmaceuticals and other stocks. Vote “Outperform” if you believe CUV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CUV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 2.5 Dividend Strength Dividend LeadershipClinuvel Pharmaceuticals is a leading dividend payer. It pays a dividend yield of 0.10%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthClinuvel Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Clinuvel Pharmaceuticals is 9.90 %. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clinuvel Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Clinuvel Pharmaceuticals is 75.91, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.50.Price to Earnings Ratio vs. SectorThe P/E ratio of Clinuvel Pharmaceuticals is 75.91, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.38.Price to Book Value per Share RatioClinuvel Pharmaceuticals has a P/B Ratio of 19.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.98 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:CUV Previous Symbol CUSIPN/A CIKN/A Webwww.clinuvel.com Phone61 3 9660 4900Debt Debt-to-Equity Ratio0.53 Current Ratio15.38 Quick Ratio14.70Price-To-Earnings Trailing P/E Ratio75.91 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$32.04 million Price / Sales35.47 Cash FlowA$1.19 per share Price / Cash Flow19.36 Book ValueA$1.20 per share Price / Book19.17Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares49,410,300Market Cap$1.14 billion Next Earnings DateN/A OptionableNot Optionable Receive CUV News and Ratings via Email Sign-up to receive the latest news and ratings for CUV and its competitors with MarketBeat's FREE daily newsletter. Clinuvel Pharmaceuticals (ASX:CUV) Frequently Asked Questions How has Clinuvel Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Clinuvel Pharmaceuticals' stock was trading at A$15.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CUV shares have increased by 49.8% and is now trading at A$23.00. View which stocks have been most impacted by Coronavirus. Has Clinuvel Pharmaceuticals been receiving favorable news coverage? News coverage about CUV stock has trended somewhat positive on Monday, InfoTrie reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Clinuvel Pharmaceuticals earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutClinuvel Pharmaceuticals. Who are some of Clinuvel Pharmaceuticals' key competitors? Some companies that are related to Clinuvel Pharmaceuticals include MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR), MorphoSys (MOR), Vir Biotechnology (VIR), MorphoSys (MOR), Abcam (ABC), BTG (BTG), Cronos Group (CRON), Kodiak Sciences (KOD), Viela Bio (VIE), Genus (GNS), Mesoblast (MSB), Polynovo (PNV), NGM Biopharmaceuticals (NGM), Concordia International (CXR) and BELLUS Health (BLU). View all competitors. What other stocks do shareholders of Clinuvel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clinuvel Pharmaceuticals investors own include Worldpay (WP), REA Group (REA), CSL (CSL), Cochlear (COH) and Afterpay Touch Group (APT). Who are Clinuvel Pharmaceuticals' key executives? Clinuvel Pharmaceuticals' management team includes the following people: Dr. Philippe Jacques Wolgen, CEO, MD & Director (Age 56)Mr. Darren M. Keamy, CFO & Company Sec. (Age 46)Dr. Dennis J. Wright BPharm, M.Sc., Ph.D., Acting Chief Scientific OfficerLachlan Hay, Gen. Mang. of Europe What is Clinuvel Pharmaceuticals' stock symbol? Clinuvel Pharmaceuticals trades on the ASX under the ticker symbol "CUV." What is Clinuvel Pharmaceuticals' stock price today? One share of CUV stock can currently be purchased for approximately A$23.00. How big of a company is Clinuvel Pharmaceuticals? Clinuvel Pharmaceuticals has a market capitalization of $1.14 billion and generates $32.04 million in revenue each year. What is Clinuvel Pharmaceuticals' official website? The official website for Clinuvel Pharmaceuticals is www.clinuvel.com. How can I contact Clinuvel Pharmaceuticals? The company can be reached via phone at 61 3 9660 4900. This page was last updated on 6/1/2020 by MarketBeat.com Staff
